Recombinant human tumor necrosis factor receptor (p75): Fc fusion protein (TNFR:Fc) in rheumatoid arthritis

Annals of Pharmacotherapy

Volumn 31, Issue 11, 1997, Pages 1335-1338

  Murray, Kim M ^a,b   Dahl, Stephen L ^c  

^a AMGEN INC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Recombinant human tumor necrosis factor receptor p75 Fc fusion protein; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; ETANERCEPT; GOLD; HYBRID PROTEIN; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT PLANNING;

EID: 0030669930     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101111     Document Type: Review

References (25)

1. Harris ED Jr. Clinical features of rheumatoid arthritis. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 4th ed. Philadelphia: WB Saunders Co., 1993:874-9.
2. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
3. Horton S, Resman-Targoff BH, Thompson DF. Use of cyclosporine in rheumatoid arthritis. Ann Pharmacother 1993;27:44-6.
4. Gabriel SE, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta analysis. Ann Intern Med 1991;115:787-96.
5. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142-6.
6. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
7. Willkens RF, Urowitz MB, Stablein DM, McDendry RJR Jr, Berger RG, Box JH, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:849-56.
8. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum 1992;35: 259-69.
9. Old LJ. Tumor necrosis factor. Sci Am 1988;258(5):59-75.
10. David J, Terhorst C. Immune response mechanisms. In: Dale DC, Federman DD, eds. Scientific American medicine. New York: Scientific American Inc., 1995,VI:III;12,13.
11. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
12. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
13. Butler DM, Feldmann M, Di Padova F, Brennan FM. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts. Eur Cytokine Netw 1994;5: 441-8.
14. Brennan FM, Maini RN, Feldmann M. TNF - a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992;31:293-8.
15. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 1990;87:3127-31.
16. Roux-Lombard P, Punzi L, Hasler F, Bas S, Todesco S, Gallati H, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993;36:485-9.
17. Krane SM, Harris ED. Rheumatoid arthritis. In: Dale DC, Federman DD, eds. Scientific American medicine. New York: Scientific American Inc., 1995,XV:II;2,3.
18. Data on file. Seattle, WA: Immunex Corporation, 1997.
19. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
20. Jacobs CA, Beckmann MP, Mohler K, Maliszewski CT, Fanslow WC, Lynch DH. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int Rev Exp Pathol 1993;34B:123-35.
21. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
22. Moreland LW, Margolies G, Heck LW, Saway A, Blosch C, Hanna R, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
23. Moreland L. Multicenter Phase II study of recombinant human tumor necrosis factor receptor fusion protein (rhu TNFR:Fc) in active rheumatoid arthritis. Presented at the Cytokines and Inflammation Meeting, Boston, MA, November 16, 1995.
24. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-9.
25. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.